Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 90,780,000
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.83
  • Price/Sales 5.71
  • Price/Cash Flow 15.34
  • Price/Book 13.44

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.83 +8.44%
on 02/02/17
36.71 -3.02%
on 02/01/17
+0.81 (+2.33%)
since 01/24/17
3-Month
31.91 +11.56%
on 11/25/16
37.08 -3.99%
on 01/05/17
+4.03 (+12.77%)
since 11/23/16
52-Week
30.89 +15.25%
on 11/23/16
57.81 -38.42%
on 04/19/16
-15.51 (-30.35%)
since 02/24/16

Most Recent Stories

More News
Notice for the Annual General Meeting of Novo Nordisk A/S

Bagsvaerd, Denmark, 24 February 2017 - The Annual General Meeting of Novo Nordisk A/S will be held on:

NVO : 35.60 (-0.50%)
Pawar Law Group Announces that a Securities Class Action Lawsuit has been filed Against Novo Nordisk A/S - NVO

NEW YORK, NY / ACCESSWIRE / February 23, 2017 / The Pawar Law Group announces a class action lawsuit on behalf of Novo Nordisk A/S. ("Novo Nordisk" or the "Company") (NYSE: NVO) investors who purchased...

NVO : 35.60 (-0.50%)
SHAREHOLDER ALERT - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novo Nordisk A/S (NVO) and Lead Plaintiff Deadline: March 13, 2017

NEW YORK, NY / ACCESSWIRE / February 23, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE:...

NVO : 35.60 (-0.50%)
NVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Novo Nordisk A/S (NYSE: NVO) securities...

NVO : 35.60 (-0.50%)
Canadian News Media Challenged to See the Whole Picture When Reporting on Obesity

The Canadian Obesity Network asks media to refresh visuals with non-biased, respectful images of people living with obesity to avoid stigmatizing portrayals

NVO : 35.60 (-0.50%)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novo Nordisk A/S (NVO) and Lead Plaintiff Deadline: March 13, 2017

NEW YORK, NY / ACCESSWIRE / February 16, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE:...

NVO : 35.60 (-0.50%)
NVO INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Novo Nordisk A/S

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased or otherwise acquired the securities of...

NVO : 35.60 (-0.50%)
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Novo Nordisk A/S (NVO) and Lead Plaintiff Deadline: March 13, 2017

NEW YORK, NY / ACCESSWIRE / February 14, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE:...

NVO : 35.60 (-0.50%)
NVO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Novo Nordisk A/S and a Lead Plaintiff Deadline of March 13, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Novo Nordisk A/S (NYSE:...

NVO : 35.60 (-0.50%)
Whitehouse Laboratories to Co-Present with Novo Nordisk at PDA Parenteral Packaging Conference

Whitehouse Laboratories is excited to announce that Brandon Zurawlow, Associate Director of Container Closure Integrity Testing(CCIT), will be participating as a co-speaker at the PDA Europe Parenteral...

NVO : 35.60 (-0.50%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Support & Resistance

2nd Resistance Point 35.76
1st Resistance Point 35.68
Last Price 35.60
1st Support Level 35.47
2nd Support Level 35.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.